Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 – New breast cancer research incorporating  the SymphonyTM suite of genomic tests (MammaPrint®, BluePrint® and TargetPrint®) will be presented in 10 scientific posters at the upcoming 2013 San Antonio Breast Cancer Symposium (SABCS), Dec. 10-14.
“These ten studies further demonstrate Agendia’s continued commitment to providing the oncology community and their breast cancer patients with the most comprehensive and validated picture of tumor biology available in the market,” said Neil Barth, M.D., Agendia’s Chief Medical Officer.
Symphony is the only widely available test suite providing molecular subtyping — a recent advancement in breast cancer prognosis and treatment that is highlighted in several SABCS posters. The second-generation MammaPrint test provides definitive High Risk or Low Risk information about breast cancer recurrence, with no “intermediate” results. To learn more about the Agendia tests, SABCS attendees can visit Booth #456.
Among the SABCS posters featuring genomic tests from Agendia are:
Wednesday, December 11, 2013
Poster P1-02-02, Session 1:  “Concordance of microarray based determination of ER, PR and HER2 receptor status and local IHC/FISH assessment in the prospective Neo-adjuvant Breast Registry Symphony Trial (NBRST).” Authors:  Beitsch P, Gittleman M, Akbari S, Stork-Sloots L, de Snoo F, Bigson J, Whitworth P.
Exhibit Halls A-B, Time 5-7 p.m.
Poster P1-08-02, Session 1:  “Chemosensitivity and endocrine sensitivity predicted by MammaPrint and BluePrint in the prospective Neo-adjuvant Breast Registry Symphony Trial (NBRST).”  Authors:  Whitworth P, Gittleman M, Akbari S, Stork-Sloots L, de Snoo F, Gibson J, Beitsch P.
Exhibit Halls A-B, Time 5-7 p.m.
Poster OT1-2-02, Session 1:  “PROMIS: Prospective study of MammaPrint in breast cancer patients with an intermediate recurrence score (PROMIS).”  Authors:  Soliman HH, Untch S, Stork-Sloots L.
Exhibit Halls A-B, Time 5-7 p.m.
Thursday, December 12, 2013
Poster P2-11-13, Session 2:  “The 70-gene signature (70-GS) in a lymph node-negative patient series with intermediate risk 21-gene recurrence scores (RS) and known adjuvant treatment recommendations.”  Authors: Lo SS, Mai H, McCroskey Z, Guo R, Ersahin C, Gaynor ER, Robinson PA, Albain KS.
Exhibit Halls A-B, Time 7-9 a.m.
Poster P2-11-23, Session 2:  “MammaPrint and BluePrint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping.”  Authors:  Yao K, Turk M, Kaul K, Wesseling J, Stork-Sloots L, de Snoo F, Cristofanilli M.
Exhibit Halls A-B, Time 7-9 a.m.
Saturday, December 14, 2013
Poster P6-06-50, Session 6:  “Obesity and the influence on tumor biology as determined by the intermediate risk 21-gene recurrence scores (RS) and the 70-gene breast cancer recurrence signature (70-GS) assay.”  Authors: Robinson P, Mai H, Guo R, Gaynor E, McCroskey Z, Ersahin C, Albain K, Lo S.
Exhibit Hall C, Time 7:30 – 9 a.m.
MammaPrint is the first FDA-cleared test to determine recurrence risk in breast cancer patients. Symphony is the only predictive, multi-gene breast cancer panel that is based on prospective trials including outcome data (e.g., the RASTER study). The Agendia tests have substantial insurance coverage encompassing an estimated 170 million lives and including coverage by Medicare and regional and national insurers.
SABCS will be held Dec. 10-14 in the Henry B. Gonzalez Convention Center, in San Antonio, Texas.
About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer Symphony suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint™­­, a molecular subtyping assay, and TargetPrint®, an ER/PR/HER2 expression assay. Together, these tests help physicians determine a patient’s individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials. For more information, visit www.agendia.com.
Liz Dowling (Medical & Consumer Media)
Dowling & Dennis Public Relations
Matt Clawson or
Len Hall (Financial Media)
Allen & Caron Inc. 949-474-4300